The results implied that the OTUB1/β-catenin axis promotes the tumorigenesis and progression of BLCA, targeting the OTUB1/β-catenin axis or applying XAV-939 might be the potential therapeutic strategy for BLCA patients. Here, OTUB1 is linked to bladder transitional cell carcinoma.